ClinicalTrials.gg
CompletedNCT04352361Updated Jul 7, 2020

Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

A Phase 1 interventional study of TVB-2640 and Placebo in Healthy, sponsored by Ascletis Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-07.

Sponsored by Ascletis Pharmaceuticals Co., Ltd. (part of Ascletis Pharma Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Ascending oral single-dose study to evaluate the safety and pharmacokinetics of TVB- 2640 tablets in the Chinese healthy population.

Read the detailed description

This study is designed as a single-center, randomized, single-blind, placebo-controlled, single-dose escalation trial. The dose groups are 25 mg, 50 mg and 75 mg respectively. The next dose should be tested only if the previous dose has demonstrated to be safe and tolerated, and each subject will receive either the experimental drug or a placebo only once.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Ascletis Pharmaceuticals Co., Ltd. is the lead sponsor of 25 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages 18 to 45 (including 18 and 45), both male and female(The 50mg dose half male and half female).
  2. Male weight ≥50 kg, female weight ≥45 kg; between 19 and 24 kg/m2 (including boundary value).
  3. Those who have no family planning within half a year and are willing to take effective measures within half a year after the last administration.
  4. Non-pregnant or lactating women.
  5. Voluntarily signing the .

Exclusion criteria

Exclusion Criteria:

  1. Persons who have or are currently suffering from any serious clinical diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities or any other diseases (eye diseases such as corneal edema, keratitis, uveitis etc.) that can interfere with the test results.
  2. Previous corneal surgery, gastrointestinal surgery, vagus neurotomy, intestinal resection or any surgical operation that may interfere with gastrointestinal peristalsis, pH or absorption (except hernia repair, appendectomy).
  3. Persons with allergic constitution, including those with allergic history of drugs, food or other substances.
  4. Those who have used any prescription drugs, over-the-counter drugs, any vitamin products or herbs within 14 days prior to administration.
  5. Any drugs that inhibit or induce the liver to metabolize drugs (e.g., inducers - barbiturates, carbamazepine, phenytoin sodium, rifampicin) were used within 30 days prior to administration; Inhibitors - SSRI antidepressants, cimetidine, cyclosporine, macrolides, verapamil, quinolones, pyrrole antifungal agents, protease inhibitors, etc.), p-gp inducers (including rifampicin, st. John's wort, okazepine, and modafinil).
  6. Smokers or those who smoked more than 5 cigarettes per day in the 3 months before the study.
  7. Alcoholics or regular drinkers in the 6 months prior to the trial, i.e., drinking more than 14 units of alcohol per week (1 unit =360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine).
  8. Drinking excessive amounts of tea, coffee or caffeinated beverages (more than 8 cups, 1 cup =250 mL) every day for 3 months before the first administration.
  9. Anyone who has consumed or plans to consume any food or beverage containing caffeine (such as coffee, strong tea, chocolate, etc.) or foods rich in xanthine (such as sardines, animal livers, etc.) or beverages within 48 hours prior to the first use of the study drug.
  10. Had consumed or planned to consume grapefruit or grapefruit-related citrus fruits (such as lime, grapefruit), star fruit, papaya, pomegranate or more fruit products within 3 days prior to administration.
  11. Patients who had donated blood or lost more than 400ml of blood within 3 months before administration.
  12. Patients who had participated in other clinical trials and received the study drug treatment within 3 months prior to the initial administration.
  13. Those who had used the first oral pill within 30 days prior to the first administration, or those who had used long-acting estrogen or progesterone injections or implants within 6 months prior to the first administration.
  14. Those who had unprotected sex within 14 days before the first administration (female).
  15. Those who have special requirements on diet and cannot follow the unified diet.
  16. Those who have worn contact lenses or contact lenses within 7 days before medication administration.
  17. Those who fail the alcohol test or abuse the positive drug screening.
  18. Abnormal vital signs with clinical significance (normal range: 90 mmHg≤ systolic blood pressure \<140 mmHg, 60 mmHg≤ diastolic blood pressure \<90 mmHg, 60 beats/min ≤ pulse (resting) ≤100 beats/min;(subject to the judgment of the study physician) or medical examination, , laboratory examination, breathalyzer test, drug abuse screening, etc.
  19. In addition to the above, the researchers judged that the patients were not suitable to participate in the clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    TVB-2640 tablets

    Drug: TVB-2640

  • Placebo comparator
    placebo

    Drug: Placebo

Interventions

  • TVB-2640 tablets (25mg/50mg/75mg) one tablet at a time, once per day.

  • DrugPlacebo

    Oral, matching number of placebo Tablets with active arm.

06

What researchers measure

Primary outcomes

  1. Evaluation of the safety and tolerability of TVB-2640 in Chinese healthy volunteers: adverse events and serious adverse events

    Evaluation of number of patients reported with adverse events and serious adverse events.

    Time frame: Up to 4 days

Secondary outcomes

  1. Evaluate the Cmax of TVB-2640

    Evaluate the Peak Plasma Concentration after a single oral dose of TVB-2640 administered to Chinese healthy volunteers.

    Time frame: Up to 3 days

  2. Tmax of TVB-2640

    Evaluate the Time to reach the maximum plasma concentration after a single oral dose of TVB-2640 administered to Chinese healthy volunteers.

    Time frame: Up to 3 days

  3. AUC of TVB-2640

    Evaluate the Area under the plasma concentration versus time curve after a single oral dose of TVB-2640 administered to Chinese healthy volunteers.

    Time frame: Up to 3 days

  4. t1/2 of TVB-2640

    Evaluate the Terminal-Phase Half-Life after a single oral dose of TVB-2640 administered to Chinese healthy volunteers.

    Time frame: Up to 3 days

  5. CL/F of TVB-2640

    Evaluate the Apparent Systemic Clearance after a single oral dose of TVB-2640 administered to Chinese healthy volunteers.

    Time frame: Up to 3 days

  6. Vd/F of TVB-2640

    Evaluate the Apparent Volume of Distribution after a single oral dose of TVB-2640 administered to Chinese healthy volunteers.

    Time frame: Up to 3 days

07

Study locations

1 site
  • Hunan provincial people's hospital
    Changsha, Hunan 410002, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2020 to primary completion in Apr 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2020
First posted
Apr 20, 2020
StartActual
Apr 2, 2020
Primary completionActual
Apr 29, 2020
CompletionActual
Apr 29, 2020
Last update
Jul 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04352361
Responsible party
Sponsor
First posted
Apr 20, 2020
Start date
Apr 2, 2020
Primary completion
Apr 29, 2020
Completion
Apr 29, 2020
Last update
Jul 7, 2020

Study contacts

Yahong Chen, MD
study director · Ascletis Pharmaceuticals Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TVB-2640

Start the discussion